Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Creighton A. M., Hellmann K., Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature. 1969 Apr 26;222(5191):384–385. doi: 10.1038/222384a0. [DOI] [PubMed] [Google Scholar]
- Hellmann K., Burrage K. Control of malignant metastases by ICRF l59. Nature. 1969 Oct 18;224(5216):273–275. doi: 10.1038/224273a0. [DOI] [PubMed] [Google Scholar]
- Hellmann K., Field E. O. Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy. J Natl Cancer Inst. 1970 Mar;44(3):539–543. [PubMed] [Google Scholar]
- Hellmann K., Newton K. A., Whitmore D. N., Hanham I. W., Bond J. V. Preliminary clinical assessment of I.C.R.F. 159 in acute leukaemia and lymphosarcoma. Br Med J. 1969 Mar 29;1(5647):822–824. doi: 10.1136/bmj.1.5647.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lewis M. G., Ikonopisov R. L., Nairn R. C., Phillips T. M., Fairley G. H., Bodenham D. C., Alexander P. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J. 1969 Sep 6;3(5670):547–552. doi: 10.1136/bmj.3.5670.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Salsbury A. J., Burrage K., Hellmann K. Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic. Br Med J. 1970 Nov 7;4(5731):344–346. doi: 10.1136/bmj.4.5731.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]